TPST

Tempest Therapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.81
52-Week Range: $0.74 – $12.23
Market Cap: $13.70M
P/E (TTM): —
EPS (TTM): -3.93
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 14.23
PEG Ratio: —
Return on Equity: -931.14%
Return on Assets: -79.37%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.38
Debt/Equity: —
Total Debt: $7.56M
Free Cash Flow: $-15.51M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $19.74M

TPST Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$22.53M	$17.50M	$28.48M	$12.61M
Selling, General & Admin	$12.11M	$11.66M	$13.55M	$13.97M
Operating Expenses	$34.64M	$29.16M	$42.03M	$26.57M
Operating Income	-$34.64M	-$29.16M	-$42.03M	-$26.57M
EBITDA	-$33.45M	-$27.66M	-$40.14M	-$25.79M
Pretax Income	-$35.71M	-$29.49M	-$41.84M	-$26.26M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$35.71M	-$29.49M	-$41.84M	-$26.26M
Diluted EPS	-40.17	-24.83	-19.50	-6.33
Diluted Shares	888947	1.19M	3.38M	4.15M

TPST Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$31.23M	$39.23M	$30.27M	$7.71M
Receivables	$450.00K	$0.00	—	—
Current Assets	$32.95M	$40.36M	$31.47M	$8.27M
Total Assets	$46.09M	$51.60M	$41.49M	$16.93M
Current Liabilities	$7.28M	$9.41M	$14.22M	$3.31M
Long-Term Debt	$10.37M	$6.26M	—	—
Total Debt	$22.11M	$20.66M	$15.37M	$8.14M
Total Liabilities	$27.98M	$24.84M	$22.36M	$10.26M
Retained Earnings	-$135.77M	-$165.26M	-$207.11M	-$233.37M
Shareholders' Equity	$18.11M	$26.77M	$19.13M	$6.67M
Working Capital	$25.67M	$30.95M	$17.25M	$4.96M

TPST Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$31.07M	-$27.36M	-$33.03M	-$26.82M
Capital Expenditure	-$562.00K	-$170.00K	-$435.00K	—
Free Cash Flow	-$31.63M	-$27.53M	-$33.46M	-$26.82M
Depreciation & Amortisation	$638.00K	$381.00K	$389.00K	$266.00K
Stock-Based Compensation	$1.56M	$2.55M	$5.30M	$3.12M
Investing Cash Flow	-$562.00K	-$170.00K	-$435.00K	$0.00
Financing Cash Flow	$11.40M	$35.60M	$24.50M	$4.26M
Net Change in Cash	-$20.23M	$8.07M	-$8.96M	-$22.56M

TPST Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.63M	$3.87M	$570.00K	$539.00K	$114.00K	$1.82M
Selling, General & Admin	$3.31M	$4.09M	$3.03M	$3.54M	$5.42M	$3.43M
Operating Expenses	$10.94M	$7.97M	$3.60M	$4.08M	$5.54M	$5.25M
Operating Income	-$10.94M	-$7.97M	-$3.60M	-$4.08M	-$5.54M	-$5.25M
EBITDA	-$10.63M	-$7.76M	-$3.44M	-$3.96M	-$27.64M	-$5.18M
Pretax Income	-$10.86M	-$7.87M	-$3.51M	-$4.02M	-$27.70M	-$5.24M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$10.86M	-$7.87M	-$3.51M	-$4.02M	-$27.70M	-$5.24M
Diluted EPS	-41.08	-2.07	-0.79	—	-2.53	-0.34
Diluted Shares	3.52M	3.80M	4.44M	—	10.93M	15.22M

TPST Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$21.51M	$14.28M	$7.51M	$7.71M	$1.80M	$779.00K
Current Assets	$22.43M	$15.10M	$8.10M	$8.27M	$2.45M	$1.70M
Total Assets	$32.16M	$24.48M	$17.13M	$16.93M	$10.75M	$9.63M
Current Liabilities	$13.18M	$7.14M	$3.52M	$3.31M	$3.31M	$4.45M
Total Debt	$13.11M	$8.66M	$8.40M	$8.14M	$7.85M	$7.56M
Total Liabilities	$21.03M	$14.70M	$10.78M	$10.26M	$9.93M	$10.72M
Retained Earnings	-$217.97M	-$225.84M	-$229.35M	-$233.37M	-$270.07M	-$275.32M
Shareholders' Equity	$11.13M	$9.78M	$6.35M	$6.67M	$822.00K	-$1.09M
Working Capital	$9.26M	$7.96M	$4.58M	$4.96M	-$865.00K	-$2.75M

TPST Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$8.04M	-$8.43M	-$6.78M	-$3.57M	-$7.60M	-$2.78M
Free Cash Flow	-$8.04M	-$8.43M	-$6.78M	-$3.57M	-$7.60M	-$2.78M
Depreciation & Amortisation	$68.00K	$67.00K	$66.00K	$65.00K	$60.00K	$60.00K
Stock-Based Compensation	$1.39M	$1.09M	$61.00K	$576.00K	$226.00K	-$117.00K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	-$721.00K	$1.20M	$13.00K	$3.77M	$1.70M	$1.75M
Net Change in Cash	-$8.76M	-$7.23M	-$6.77M	$193.00K	-$5.90M	-$1.03M

Market Snapshot

About

Tempest Therapeutics is a clinical-stage biotechnology company developing cancer immunotherapy treatments. The company focuses on novel small molecule therapeutics targeting the tumor microenvironment to improve patient outcomes. Tempest is advancing multiple programs through clinical trials for various oncology indications.